Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

NGEN Stock Latest News

The FlyNervGen Pharma doses first participant in RESTORE trial3w agoNGEN

Company AnnouncementsNervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results1M ago6K NGEN
The FlyNervGen Pharma to restate previously filed financial statements1M agoNGEN
Company AnnouncementsNervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors1M agoNGEN
Company AnnouncementsNervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation1M ago6K NGEN

NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year

The FlyNervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year2M agoNGEN

Company AnnouncementsNervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position2M ago6K NGEN

The FlyNervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright3M agoNGEN

The FlyNervGen Pharma initiated with an Outperform at Leerink3M agoNGEN
Company AnnouncementsNervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners4M ago6K NGEN
The FlyNervGen Pharma initiated with a Buy at TD Cowen4M agoNGEN
Company AnnouncementsNervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program5M ago6K NGEN

Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors

Company AnnouncementsNervgen’s CONNECT Trial Termination: What It Means for NGEN Investors5M agoNGEN

Company AnnouncementsNervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 35M ago6K NGEN

The FlyNervGen Pharma files $250M mixed securities shelf5M agoNGEN

The FlyNervGen Pharma announces biomechanical gait analyses on recovery with NVG-2915M agoNGEN
Company AnnouncementsNervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development5M ago6K NGEN
The FlyNervGen Pharma 24M share Spot Secondary priced at $2.505M agoNGEN
The FlyNervGen Pharma secondary being re-offered at $2.50 per share5M agoNGEN

NervGen Pharma announces common share offering, no amount given

The FlyNervGen Pharma announces common share offering, no amount given5M agoNGEN

Company AnnouncementsNervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows5M ago6K NGEN

The FlyNervGen Pharma reports Q1 EPS (2c), consensus (7c)5M agoNGEN